



Ease-a-Cold pulled

POPULAR Ease-a-Cold Cough Cold & Flu Day & Night from Pharmacare Laboratories has had its medicines advertising approval withdrawn by the Therapeutic Goods Administration (TGA).

The TGA says the grounds for withdrawal are because of a change to the facts or circumstances existing when the advertisement was approved, it no longer complies with the Therapeutic Goods Advertising Code.

PhD scholarships open

HIGHER degree research students with an interest in the fields of mental health and herbal medicine are encouraged to apply for two new scholarships available at the National Institute of Complementary Medicine (NICM), Western Sydney University.

WESTERN SYDNEY UNIVERSITY



Provided in partnership with the Blackmores Institute, the scholarships will support two PhD students over three years.

BLACKMORES
Australia's No.1 Brand

The mental health PhD project will involve the design and study of an integrative model to treat depression, including nutraceuticals and lifestyle medicine under Professor Jerome Sarris.

Candidates who would like to apply can do so online until Mon 26 Nov at nicm.edu.au.

AHPRA & PBA research focus

THE Australian Health Practitioners Regulatory Authority (AHPRA) and the Pharmacy Board of Australia (PBA) have announced the Annual Report for AHPRA and the National Boards for the year to 30 Jun 2017 is now available to view online - ahpra.gov.au.

"The theme of the year was research," explained PBA chair William Kelly.

"On behalf of the Board, AHPRA's Risk-based Regulation Unit completed a study of complaints about pharmacists, which provided an evidence base to better inform the development of regulatory standards for the profession."

The Board also continued its consultation into proposals for revised guidance on the compounding of sterile injectable medicines and funded and participated in the review of the national competency standards framework for pharmacists in Australia 2016, as well as piloting a survey of interns and preceptors to look into issues relevant to the quality of intern training experience.

"The Board proactively engaged the profession and stakeholders to ensure the information and guidance provided is easy to understand, up-to-date and relevant," said Kelly.

"This work included updating website content and revising a guide for oral examination candidates."

Other elements of the report highlight the largest online registration renewal rate ever

achieved across all 14 registered health professions.

More than 98.5% of all registered health practitioners renewed online and on time, with 99.1% of pharmacists renewing online.

Pharmacists comprise 4.5% of all health practitioners and the registrant base continues to grow (up 2.2% from 2015/16 to 30,360).

A significant number (373) of notifications were lodged about pharmacists in 2016/17.

This equated to 1.8% of the profession, the report said.

Of the 355 matters closed, 18% resulted in the Board accepting an undertaking or conditions being imposed, 30.1% resulted in a caution or reprimand, 1.7% resulted in suspension or cancellation of registration, and 49.3% resulted in no further action being taken.

Of the 53 statutory offence complaints made about pharmacists in 2016/17 (up from 13 in 2015/16), the majority (40) were about advertising breaches while 13 complaints related to use of a protected title.

FDA flags kratom risk

THE US Food and Drug Administration (FDA) has issued a safety alert to healthcare professionals and consumers around a harmful unapproved imported botanical substance called kratom.

Kratom is a plant that grows naturally in Thailand, Malaysia, Indonesia and Papua New Guinea.

It has gained popularity in the US, with some marketers touting it as a "safe" treatment with broad healing properties.

Proponents argue that it's a safe substance largely because it's a plant-based product, but the FDA points out that kratom has similar effects to narcotics like opioids, and carries similar risks of abuse, addiction and in some cases, death.

Kratom is already a controlled substance in 16 countries, including Australia, two of its native countries of origin Thailand and Malaysia, as well as Sweden and Germany.

It is also banned in several states, specifically Alabama, Arkansas, Indiana, Tennessee and Wisconsin while several others have pending legislation to ban it.

Osteoarthritis on NPS radar

NPS Medicinewise has released an "Insights" page to healthcare professionals saying medicines have a limited role for osteoarthritis, and "treatment now focuses on education, exercise and weight".

In addition, the government organisation says that imaging also has a limited role and that the management of osteoarthritis

has shifted from a "traditional approach of pain control to core management strategies including education and information, weight management and physical activity".

NPS made special reference to opioids, saying they offer "limited benefits and a significant risk of harm".

See nps.org.au for resources.

DermAid 1%
Dissolved to work fast.

The only dissolved hydrocortisone* for fast, temporary relief of minor skin irritations

DERMATITIS/ ECZEMA | ITCHY RASHES | SCALP IRRITATIONS | SUNBURN | INSECT BITES | JEWELLERY RASHES

*In Australia, DermAid is indicated for the temporary relief of minor skin irritations, itching and rashes due to eczema, dermatitis, cosmetics, jewellery, itching genital and anal areas, sunburn. DermAid 1% spray: Hold bottle approx. 10cm from the affected areas and apply 1-2 sprays; 2-3 times daily as required. Massage in gently. Healthcare professionals: Review the full Product Information (PI) before recommending DermAid 1% spray. PI available upon request from Ego Pharmaceuticals.

THE PAIN BARRIER

ZOSTRIX
CAPSAICIN 0.025% W/W
Topical Analgesic Cream

ZOSTRIX BLOCKS NERVE PAIN
associated with arthritis, pain & post shingles pain.

LINK
A GLENHEIM COMPANY

Luminarie

BRAND SOLUTIONS AUSTRALIA

Luminarie, together with Brand Solutions Australia are pleased to be now supporting Zostrix

www.zostrix.com.au

Always read the label. Use only as directed. If symptoms persist consult your pharmacist or healthcare professional. Zostrix is the registered trade mark of Link Medical Products Pty Ltd, Warriewood NSW 2102. Phone 1800 181 060

Stay up to date
on the go

Download the app



Pharmacy Daily

Trackable tablets

THE US Food and Drug Administration has approved the first therapeutic pill that can be digitally tracked on its path through the body.

The Abilify MyCite aripiprazole tablets, for treating schizophrenia and manic episodes, have an ingestible sensor embedded inside them that records that the medication has been taken.

A patch worn by the patient transmits this information to their smartphone and can also be sent to the prescribing doctor, if the patient consents to this.

About the size of a grain of sand, the sensor activates when it comes into contact with stomach fluid.

The hope is that the technology could improve medication compliance for these patients.

Antibiotic management key

NEW data has found that antibiotic stewardship programmes can reduce the number of hospital infections caused by multidrug-resistant bacteria by 51%, the UK National Institute for Health and Care Excellence (NICE) has highlighted.

The research, published in *The Lancet*, also shows the number of people experiencing drug-resistant infections decreases further when infection control measures, such as good hand hygiene, are followed.

NICE says, healthcare professionals should select the dose, length of treatment and type of administration (for example, tablets or injection) that is right for the person and the infection.

"This stewardship helps to fight resistance because it preserves the

usefulness of antibiotics."

NICE deputy chief executive Professor Gillian Leng said, "Antibiotic resistance is a concern for us all."

"If we do not act now we face a future where these medicines will no-longer work, which would mean people would die from routine surgery and other common infections we can currently treat.

"Stewardship programmes only work when everyone is on the same page.

"It can be hard work, but this new research shows the difference we can make when we work together. It is very good news."

Multidrug-resistant infections are caused by bacteria that can survive treatment with more than one antibiotic and are more commonly found in a hospital environment, NICE emphasises.

The health organisation is reviewing its guidelines for 'Antimicrobial stewardship' inviting feedback until 5pm GMT on Mon 20 Nov - **CLICK HERE** to submit.

More research funds

THE Federal Government announced this week its investment in the future at the University of Newcastle with \$12.2m to fund 19 major medical research projects.

Provided through the National Health and Medical Research Council (NHMRC), these grants will allow the university to continue research into the diagnosis, treatment and prevention of diseases such as asthma, emphysema and influenza.

Minister for Health, Greg Hunt, said, "The University of Newcastle has an exceptional record of producing high-quality health and medical research.

"The funding announced today will assist in key health areas, especially indigenous health and those suffering from chronic disease."

Pro Vice-Chancellor Health and Medicine, Laureate Professor John Aitken said, "Cancer, stroke and respiratory diseases are just some of the important issues that will be the focus of our research projects as a result of today's funding..."

Win with Plunkett's

Everyday this week Pharmacy Daily and Plunkett's are giving away a NS prize pack valued at \$30 each.

NS Working Hands...an intensive, non-greasy, non-slip hand treatment that absorbs instantly and leaves an invisible skin protection barrier that locks in the natural ingredients to restore dry, cracked, calloused and split hands. NS Working Hands leaves hands moisturised without the grease factor... so hands can get back to work, fast! Visit: www.nsWorkingHands.com.au



To win, be the first from SA or NT to send the correct answer to the question to comp@pharmacydaily.com.au

What is the name of the natural clay mineral that stops skin feeling slippery or greasy?

Check here tomorrow for today's winner.

1st stroke ambulance

AUSTRALIA'S first ever "Stroke Ambulance", a possible game-changer in time critical stroke treatment, will take to the road in Melbourne this month.

Stroke Foundation ceo Sharon McGowan joined Victorian Premier Daniel Andrews, Minister for Health Jill Hennessy and representatives from the Royal Melbourne Hospital, Ambulance Victoria, the University of Melbourne and The Florey Institute of Neuroscience and Mental Health to officially launch the Mobile Stroke Unit this week.



The Mobile Stroke Unit (pictured) is a five-tonne purpose built vehicle, designed to provide the quickest possible diagnosis and treatment for patients suffering a life threatening stroke.

It features a CT (Computed Tomography) scanner and will be staffed by a neurologist, stroke nurse, radiographer and Ambulance Victoria paramedics.

HPS Pharmacies

Pharmacist in Charge

Based at John Fawcner Private Hospital in Coburg

- Newly created, full time position
- Exciting Management Opportunity
- Oncology and manufacturing focus

We are currently seeking a suitably qualified candidate for our newly created Pharmacist-in-Charge role, based at John Fawcner Private Hospital in Coburg.

The Pharmacist-in-Charge will lead a small team of experienced staff, with the support of an off-site Pharmacy Manager. The role requires the preparation of cytotoxic medications, clinical screening of oncology and haematology protocols and the provision of a clinical pharmacy service with drug information and education and managing clinical trials/compassionate access programs.

Why not have a confidential conversation with us about this opportunity? We'd appreciate the opportunity to hear from you and discuss what you're looking for in your pharmacy management career.


For more information please contact Stephen Hon, Pharmacy Manager at Stephen.Hon@hpspharmacies.com.au.

To apply, visit www.hps.com.au/careers

Love cruising?

Subscribe to
Cruise Weekly

CRUISE
WEEKLY



Dispensary Corner

EATING chocolate five times a week reduces an overweight person's risk of having a heart attack, new research suggests.

The VA Boston Healthcare System found those carrying too much weight and indulge in the treat at least five times a week are least likely to have a coronary artery disease (CAD)-related event, such as a heart attack.

The study revealed that overweight people who never eat chocolate are the most at risk of suffering a CAD-related event.

Dark chocolate was found to improve heart health due to its antioxidants protecting against 'bad' cholesterol, while boosting blood flow, lowering blood pressure and preventing clots.



MORE women are freezing their eggs than ever before as an insurance policy while they chase their career goals, however very few of these women have ever thought about turning the experience into an online image gallery.

Gina Lopez, 35, has decided to pose in a series of photos holding her eggs to keep the experience very "humorous and very public".

But before you turn the overshare dial up to maximum, they are only symbolic eggs and not the real thing - phew!

Lopez was rumored to have made a giant omelette following the shoot, outraging misguided right-to-lifers.

SMS alerts up vaccine rates

WITH seasonal influenza vaccine recommended and funded for groups at higher risk of serious infection, it is unfortunate that uptake is suboptimal, but there is light at the end of the tunnel, according to West Australian researchers published in the *Annals of Family Medicine*.

They conducted a randomized controlled trial of short message service (SMS) reminders for influenza vaccination revealing that SMS reminders were a "modestly effective, low-cost means to increase seasonal influenza vaccine coverage among high-risk patients".

Six weeks after seasonal influenza vaccinations began, the scientific group identified high-risk patients who had a mobile telephone number on record at 10 practices in Western Australia.

Of the 12,354 eligible patients at each practice one-half were randomly assigned to receive

a vaccination reminder by SMS (intervention) and the rest received no SMS (control).

Vaccination data were extracted from the patients' electronic medical records to be analysed.

The greatest impact was reported among children under five years of age because their parents were more than twice as likely to have their child vaccinated if they received a text message reminder.

Analysis revealed that for every 29 reminder text messages sent, one extra high-risk patient was immunised, providing a scientific patient-centred basis for vaccinators to use this communication means to increase vaccination rates in Australia.

Access the study in full at annfamned.org.



Diabetes study boost

TYPE 1 diabetes (T1D), affecting approximately 150,000 Australians, has long been considered incurable, but is about to get a major boost in the form of a Federal Government research grant of \$9.46m.

The project will be run by St Vincent's Institute of Medical Research in Melbourne and headed by Professor Thomas Kay, will focus on three intersecting themes.

Firstly, it will focus on early life and understanding why T1D develops.

Secondly, it will investigate prevention and seek to identify new drugs to stop the disease from occurring.

Thirdly, it will explore treatment, aiming to improve therapies to replace the cells that are destroyed during the disease process.

Visit nhmrc.gov.au for details.

Vit D research award

RESEARCH into brain development and schizophrenia has led to international acclaim for The University of Queensland's Professor John McGrath, recipient of Denmark's Strömrgren Medal.

As Queensland Brain Institute researcher and director of the Queensland Centre for Mental Health Research, McGrath and his team demonstrated low vitamin D status in pregnant women and babies could affect brain development and increase risk of schizophrenia later in life.

When accepting the award, McGrath will also deliver the medal's accompanying Erik Strömrgren Lecture.



Travel Specials

WELCOME to *Pharmacy Daily's* travel feature. Each week we highlight a couple of great travel deals for the pharmacy industry, brought to you by *Cruise Weekly*.

CRUISE
WEEKLY

Sponsored by *Cruise Weekly*
your FREE cruise newsletter
Subscribe now

www.cruiseweekly.com.au

Oceania Cruises OLife Choice offers

EXPLORE Europe and The Americas or many other options in 2019 with outstanding offers from Oceania Cruises such as 50% off deposits, a US\$100 shipboard credit per stateroom on select voyages and OLife Choice, which includes free unlimited internet, plus choose one of these free options: shore excursions, beverage package or more shipboard credit.

The opportunities for exploration are limitless, and the experiences will be unforgettable.

Visit oceaniacruises.com.

APT Cruising Featured Special Deals

BOOK selected APT cruises and tours in any suite category year round by 30 Nov 2017 and fly free to Europe as well as receiving a free suite upgrade.

This special time-bound offer includes air taxes of up to \$300 per person.

Alternatively choose Canada or Vietnam and Cambodia.

See aptouring.com.au.

Pharmacy Daily

www.pharmacydaily.com.au

Pharmacy Daily is part of the Business Publishing Group family of publications.

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL

Editor in Chief and Publisher – Bruce Piper
Managing Editor – Jon Murrie
Reporter – Mal Smith

Contributors – Jasmine O'Donoghue, Matt Bell, Adam Bishop
info@pharmacydaily.com.au

ADVERTISING AND MARKETING

Sean Harrigan and Melanie Tchakmadjian
advertising@pharmacydaily.com.au

BUSINESS MANAGER

Jenny Piper
accounts@pharmacydaily.com.au

Suite 1, Level 2, 64 Talavera Rd
Macquarie Park NSW 2113 Australia
PO Box 1010 Epping NSW 1710 Australia
Tel: 1300 799 220 (+61 2 8007 6760)

Sign up free at
www.pharmacydaily.com.au

Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

Travel Daily
CRUISE
WEEKLY

travelBulletin
business events news